| Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. | |
| | |
MedLine Citation:
|
PMID: 19739234 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Homoharringtonine (HHT) is a natural alkaloid that is obtained from various Cephalotaxus species. The mechanism of action by which HHT exerts its antitumor activity is through inhibition of protein synthesis and promotion of apoptosis. In the 1990s, HHT proved to be significantly active as salvage therapy for patients with chronic myeloid leukemia (CML) after failure on interferon-alpha therapy. However, the remarkable success of imatinib mesylate in the treatment of CML relegated HHT to oblivion. The development of omacetaxine mepesuccinate, a subcutaneously bioavailable semisynthetic form of HHT, and its activity in imatinib-resistant CML has established this agent for the second time as a valuable option in the management of this disease. Preliminary results appear to support the use of this agent for patients who have imatinib-resistant CML, including those who carry the tyrosine kinase inhibitor-insensitive mutation that exchanges the amino acids threonine and isoleucine at position 315 (the T315I mutation). In this article, the authors discuss the current data on omacetaxine and the prospects of this agent to be integrated into the state-of-the-art treatment algorithms for CML. |
| | |
Authors:
|
Alfonso Quint??s-Cardama; Hagop Kantarjian; Jorge Cortes |
Related Documents
:
|
17462954 - Vegf-targeted cancer therapy strategies: current progress, hurdles and future prospects. 806774 - Current status of dt targets for cancer therapy. 20095944 - Liposomal cancer therapy: exploiting tumor characteristics. 17674964 - Future strategies for targeted therapies and tailored patient management in pancreatic ... 9845214 - Changes in structure and functions of prostate by long-term administration of an androg... 2296564 - Nutritional deficiencies in patients receiving cancer chemotherapy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Cancer Volume: 115 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2010-01-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 5382-93 Citation Subset: AIM; IM |
Copyright Information:
|
(c) 2009 American Cancer Society. |
Affiliation:
|
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. aquintas@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Algorithms Antineoplastic Agents, Phytogenic / therapeutic use* Clinical Trials as Topic Drug Discovery Drug Resistance, Neoplasm Drug Screening Assays, Antitumor Harringtonines / chemistry, therapeutic use* Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*, genetics Piperazines / therapeutic use Pyrimidines / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Harringtonines; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib; 26833-87-4/homoharringtonine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Complex geometric models of diffusion and relaxation in healthy and damaged white matter.
Next Document: Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emissi...